Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Evaluation of Histologic and Endoscopic Remission Induced by Infliximab in Moderate to Severe Ulcerative Colitis (HERICA)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Grupo de Estudo da Doença Inflamatória Intestinal
ClinicalTrials.gov Identifier:
NCT01408810
First received: July 20, 2011
Last updated: December 17, 2012
Last verified: December 2012

July 20, 2011
December 17, 2012
February 2011
November 2012   (final data collection date for primary outcome measure)
  • histological remission [ Time Frame: histological remission were assessed at week 8 ] [ Designated as safety issue: No ]
    To assess if infliximab is able to induce histological remission in patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy, including corticosteroids and 6-MP/AZA or who are intolerant or have medical contraindications for such therapies using Geboes criteria at week 8
  • Clinical response [ Time Frame: clinical response were assessed at week 8 ] [ Designated as safety issue: No ]
    To assess the clinical response in the above patients assessed by Mayo Score at week 8
  • Clinical remission [ Time Frame: Clinical remission were assessed at week 8 ] [ Designated as safety issue: No ]
    To assess if infliximab is able to induce histological remission in patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy, including corticosteroids and 6-MP/AZA or who are intolerant or have medical contraindications for such therapies using Geboes criteria at week 8
  • Clinical response [ Time Frame: clinical response were assessed at week 8 ] [ Designated as safety issue: No ]
    To assess the clinical response in the above patients assessed by Mayo Score at week 8
Complete list of historical versions of study NCT01408810 on ClinicalTrials.gov Archive Site
  • Histologic Efficacy assessment [ Time Frame: baseline, week 8, week 30 and week 52. ] [ Designated as safety issue: No ]
    To assess the impact of infliximab histologically, four biopsies will be collected from distinct areas (two from rectum and two from sigmoid) from each patient
  • Correlate histological remission with mucosal healing,faecal calprotectin and lactoferrin levels,number of colectomies,number of hospitalizations,Number of clinical relapses [ Time Frame: up to week 52 ] [ Designated as safety issue: No ]

    Correlate histological remission with:

    Mucosal healing Faecal calprotectin and lactoferrin levels Number of colectomies up to week 52 Number of hospitalizations up to week 52 Number of clinical relapses up to week 52

Same as current
Not Provided
Not Provided
 
Evaluation of Histologic and Endoscopic Remission Induced by Infliximab in Moderate to Severe Ulcerative Colitis
Histological and Endoscopic Evaluation of Remission Induced by Infliximab in Moderately to Severely Active Ulcerative Colitis Patients

The aim of this study is to assess the relationship between microscopic Geboes index of inflammation and clinical course of ulcerative colitis in patients treated with infliximab. The investigators propose to test the hypothesis if infliximab is able to induce histological remission and then change the clinical course of ulcerative colitis.

Correlations between histologic disease activity and other assessments of clinical disease activity are not well established despite a good correlation being found between endoscopy and histology, especially during active ulcerative colitis (1,2). Endoscopic healing induced by infliximab in Crohn's disease patients was associated with a significant reduction in surgeries and hospitalizations (3). Histological recovery in ulcerative colitis is often incomplete and some studies have shown that microscopic evidence of inflammation is common even in patients with clinically and quiescent colitis assessed by sigmoidoscopy (4,5). Although this fact has not yet been completely elucidated, it is suggested that some patients with residual microscopic acute inflammation may be more prone to relapse (2). The prognostic importance of microscopic inflammation is unknown. Given that the rectum is always involved in ulcerative colitis and inflammatory activity is diffuse and restricted to the mucosa, the collection of samples from the rectal and sigmoid mucosa are potentially useful tools for evaluating disease severity. In addition, there is a strong correlation between the levels of calprotectin and the degree of inflammation as assessed by endoscopic and histologic criteria (6). Therefore, the measurement of faecal calprotectin and lactoferrin may also provide as valuable non-invasive tools to assess disease activity and optimize the treatment in UC patients.

Histologically, active disease is defined by the presence of neutrophils in conjunction with epithelial cell damage. Analysis generally relies on the examination of H & E-stained sections. Two samples are suggested as more appropriated because it is well-known that treatment may induce variations in the expression of inflammation intensity. Several histological scores were proposed, however, Geboes index (7) has been validated and tested for reproducibility and has 5 domains: structural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulceration. The Geboes index has a more elaborated grading of crypt lesions and surface epithelial damage than other proposed indexes. The aim of this study is to assess the relationship between microscopic Geboes index of inflammation and clinical course of ulcerative colitis in patients treated with infliximab. The investigators propose to test the hypothesis if infliximab is able to induce histological remission and then change the clinical course of ulcerative colitis

Interventional
Phase 4
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Ulcerative Colitis
Drug: Infliximab
5 mg/Kg, I.V. at weeks 0, 2, 6 and every 8 weeks thereafter
Other Name: Remicade
Experimental: Infliximab
Infliximab 5 mg/Kg, I.V. at weeks 0, 2, 6 and every 8 weeks thereafter. The treatment should follow infliximab's Summary of Product Characteristics.
Intervention: Drug: Infliximab
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
21
November 2012
November 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects must meet all the following inclusion criteria to be considered eligible:

    1. Must be eligible to start infliximab treatment according to the Portuguese approved Summary of Product Characteristics (SPC-See supplement 15.3)*
    2. Patients must be older than 18 years of age up to 65 years of age at the time of informed consent, of both gender and any race.
    3. Patients with moderate to severe UC - Mayo Score (6-12); endoscopic subscore ≥2
    4. Regarding the previous treatment exposure:

      4.1 Patients must have responded inadequately to corticosteroids at least a dose of 40mg/day with or without 5-ASA or patients steroid-dependent* 4.2- Patients must have responded inadequately to azathioprine or 6-MP (treatment with thiopurines must be at least 3 months in duration) or be intolerant to these agents.

    5. Patients must be naïve to infliximab or other anti-TNF agents
    6. No history of latent or active TB prior to screening. No signs or symptoms suggestive of active TB upon medical history and/or physical examination.
    7. Patients must be capable of providing written informed consent prior to trial entry.
    8. Subjects must be willing and able to adhere to visit protocol schedule and procedures.

      • Patients must have responded inadequately to corticosteroids at least a dose of 40mg/day with or without 5-ASA or patients steroid-dependent with a Mayo Score (6-12), endoscopic subscore >2. Steroid-dependent is defined as: patients unable to reduce steroids below 10mg/day within 3 months of starting steroids and patients who have a relapse within 3 months of stopping steroids.

Exclusion Criteria:

  • 1- Any "Contraindication" as specified in the Portuguese infliximab approved Summary of Product Characteristics (See Supplement 15.3) 2- Patients with severe anemia (haemoglobin<8.0 g/dL) 3- Any malignancy in the past 5 years, including lymphoproliferative disorders 4- Existence of not removed adenomatous polyps 5- History of opportunistic infections in the last 6 months 6- Subjects who have a known viral infection such as CMV, HIV, HBV or HCV 7- Patients with a history of demyelinating diseases 8- Pregnant or breastfeeding women 9- Topical treatment with 5-ASA and steroids 10-Patients with only rectal involvement
Both
18 Years to 64 Years
No
Contact information is only displayed when the study is recruiting subjects
Portugal
 
NCT01408810
P06120
No
Grupo de Estudo da Doença Inflamatória Intestinal
Grupo de Estudo da Doença Inflamatória Intestinal
Not Provided
Principal Investigator: Susana Lopes, MD Hospital de São João
Principal Investigator: Francisco Portela, MD Hospitais da Universidade de Coimbra
Principal Investigator: Paula Lago, MD Hospital Geral de Santo António
Principal Investigator: José Cotter, MD Hospital Nossa Senhora da Oliveira - Guimarães
Principal Investigator: Paula Peixe, MD Centro Hospitalar Lisboa Ocidental - Hospital Egas Moniz
Grupo de Estudo da Doença Inflamatória Intestinal
December 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP